Baseline abnormal liver function tests are more important than age in the development of isoniazid‐induced hepatoxicity for patients receiving preventive therapy for latent tuberculosis infection

No abstract is available for this paper.

• Publication year

  2016

• Venue

  Internal medicine journal (Print)

• Publication date

  2016-03-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1111/imj.12979PMID 26648478
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Completion of Treatment for Latent Tuberculosis Infection with Monthly Drug Dispensation Directly through the Tuberculosis Clinic

  2012cited by this paper
• Age-related risk of hepatotoxicity in the treatment of latent tuberculosis infection: a systematic review.

  2010cited by this paper
• Management of Latent Tuberculosis Infections in Australia and New Zealand: A Review of Current Practice

  2010cited by this paper
• Adherence to treatment for latent tuberculosis infection: systematic review of studies in the US and Canada.

  2008cited by this paper
• Adverse Events with 4 Months of Rifampin Therapy or 9 Months of Isoniazid Therapy for Latent Tuberculosis Infection

  2008cited by this paper
• Antirheumatic drugs and the risk of tuberculosis.

  2006cited by this paper
• American Thoracic Society Documents An Official ATS Statement : Hepatotoxicity of Antituberculosis Therapy

  2006cited by this paper
• Isoniazid hepatotoxicity associated with treatment of latent tuberculosis infection: a 7-year evaluation from a public health tuberculosis clinic.

  2005cited by this paper
• Effectiveness of recommendations to prevent reactivation of latent tuberculosis infection in patients treated with tumor necrosis factor antagonists.

  2005cited by this paper
• Treatment completion and costs of a randomized trial of rifampin for 4 months versus isoniazid for 9 months.

  2004cited by this paper
• Tuberculosis infection in patients with rheumatoid arthritis and the effect of infliximab therapy.

  2004cited by this paper
• Targeted Tuberculin Skin Testing and Treatment of Latent Tuberculosis Infection in Children and Adolescents

  2004cited by this paper
• Tuberculosis contact investigations: outcomes in selected areas of the United States, 1999.

  2003cited by this paper
• Evaluation of tuberculosis contact investigations in California.

  2003cited by this paper
• Use of isoniazid for latent tuberculosis infection in a public health clinic.

  2003cited by this paper
• Treatment for latent TB in correctional facilities: a challenge for TB elimination.

  2003cited by this paper
• Evaluation of tuberculosis contact investigations in California.

  2003cited by this paper
• Tuberculosis contact investigations: outcomes in selected areas of the United States, 1999.

  2003cited by this paper
• Pyrazinamide and rifampin vs isoniazid for the treatment of latent tuberculosis: improved completion rates but more hepatotoxicity.

  2003cited by this paper
• Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent

  2001cited by this paper
• Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent.

  2001cited by this paper
• Twelve months of isoniazid compared with four months of isoniazid and rifampin for persons with radiographic evidence of previous tuberculosis: an outcome and cost-effectiveness analysis.

  2000cited by this paper
• Diagnosis and monitoring of hepatic injury. I. Performance characteristics of laboratory tests.

  2000cited by this paper
• Diagnosis and Monitoring of Hepatic Injury. II. Recommendations for Use of Laboratory Tests in Screening, Diagnosis, and Monitoring

  2000cited by this paper
• Hepatotoxicity associated with isoniazid preventive therapy: a 7-year survey from a public health tuberculosis clinic.

  1999cited by this paper
• How much isoniazid is needed for prevention of tuberculosis among immunocompetent adults?

  1999cited by this paper
• Clinical presentation and outcome of tuberculosis in kidney, liver, and heart transplant recipients in Spain. Spanish Transplantation Infection Study Group, GESITRA.

  1997cited by this paper
• The use of antibiotics : a clinical review of antibacterial, antifungal, and antiviral drugs

  1997cited by this paper
• The high incidence of tuberculosis among renal transplant recipients in India.

  1996cited by this paper
• Isoniazid-related fatal hepatitis.

  1996cited by this paper
• Mycobacterium tuberculosis in lung transplant recipients.

  1995cited by this paper
• Tuberculosis in liver transplant patients.

  1994cited by this paper
• Isoniazid liver injury: clinical spectrum, pathology, and probable pathogenesis.

  1976cited by this paper
• Serum transaminase elevations and other hepatic abnormalities in patients receiving isoniazid.

  1969cited by this paper

• Association of clinical laboratory parameters with latent tuberculosis infection among healthcare workers of primary health centers―A cross-sectional observational study

  2025cites this paper
• Safety, efficacy and feasibility of preventive treatment for drug-resistant tuberculosis with moxifloxacin or bedaquiline

  2025influential citation
• Latent Tuberculosis Screening and Active Tuberculosis Disease Development in People Living with HIV: A Multicenter Retrospective Cohort Study in Turkiye.

  2025cites this paper
• Diagnosis, prevention and risk-management of drug-induced liver injury due to medications used to treat mycobacterium tuberculosis

  2024cites this paper
• Hepatotoxicity induced by isoniazid in patients with latent tuberculosis infection: a meta-analysis

  2023cites this paper
• Pulmonary tuberculosis and diabetes mellitus: Epidemiology, pathogenesis and therapeutic management (Review)

  2023cites this paper
• A pharmacovigilance study of terbinafine indication and liver enzyme elevation

  2022cites this paper
• AASLD practice guidance on drug, herbal, and dietary supplement–induced liver injury

  2022cites this paper
• Beyond the approved: target sites and inhibitors of bacterial RNA polymerase from bacteria and fungi.

  2022cites this paper
• Initial methotrexate dosage is not associated with an increased risk of liver toxicity in patients with rheumatoid arthritis

  2021cites this paper
• Association between 9-month isoniazid prophylaxis of latent tuberculosis and severe hepatitis in patients treated with TNF inhibitors

  2021cites this paper
• Completion rate of latent tuberculosis infection treatment in patients aged 65 years and older.

  2019cites this paper
• British HIV Association guidelines for the management of tuberculosis in adults living with HIV 2019

  2019cites this paper
• Screening and treatment for tuberculosis in a cohort of unaccompanied minor refugees in Berlin, Germany

  2019cites this paper
• Isoniazid promotes the anti-inflammatory response in zebrafish associated with regulation of the PPARγ/NF-κB/AP-1 pathway.

  2019cites this paper
• The Effect of Protracted Exposure to Radiation on Liver Injury: A Cohort Study of Industrial Radiographers in Xinjiang, China

  2018cites this paper
• Screening for latent and active tuberculosis infection in the elderly at admission to residential care homes: A cost-effectiveness analysis in an intermediate disease burden area

  2018cites this paper
• Drugs Used in TB and Leprosy

  2017cites this paper
• Implementing isoniazid preventive therapy in a tuberculosis treatment-experienced cohort on ART.

  2017cites this paper
• Implementing Isoniazid Preventive Therapy in a TB-treatment experienced cohort on ART

  2017cites this paper
• The strategic framework of tuberculosis control and prevention in the elderly: a scoping review towards End TB targets

  2017cites this paper